An adjuvant approach to Cancer therapy:

Innovation through simplification ...

Advantagene
440 Lexington Street
Auburndale, MA 02466

Tel  (617) 916-5445

Fax  (617) 916-5444

Info@advantagene.com

Advantagene:  Making the “Standard of Care” for cancer work better

A Phase I/II trial has also been developed in pancreatic cancer combining PancAtak™ with standard of care chemoradiation and surgery. Pancreatic cancer provides the opportunity for short-term endpoints as the median survival with standard of care is less than one year, with approximately 30,000 new cases and 30,000 deaths per year.  In addition, the performance of laparotomy for intraoperative radiation following AdV-tk and chemoradiation will allow assessment of biologic and clinical endpoints at 3 months post-therapy.  This includes assessment of transduction efficiency, TK expression, pathologic and immune response.  The laparotomy will also provide an opportunity to evaluate if treatment has significantly reduced tumor size, as a short-term indication of clinical response.  Surgery is the only possibility of cure for pancreatic cancer.  Currently about 5% of patients designated unresectable at diagnosis get designated respectable during laparotomy, an increase of this resectability rate would be a quantifiable positive outcome. This trial is currently open at Massachusetts General Hospital and may be rolled into a randomized controlled Phase II trial in the same manner as GliAtak™ with a time frame of approximately 36 months.